Drug Profile
Empagliflozin/linagliptin - Boehringer Ingelheim
Alternative Names: Ajaduo; BI 10773/BI 1356; BI 10773/linagliptin; BI 1356/BI 10773; BI 1356/empagliflozin; Empa/Lina FDC; Empagliflozin/BI 1356; Glyxambi; Linagliptin/BI 10773; Linagliptin/empagliflozin; Tiptengio; TradianceLatest Information Update: 08 Mar 2023
Price :
$50
*
At a glance
- Originator Boehringer Ingelheim
- Developer Boehringer Ingelheim; Eli Lilly; Eli Lilly and Company
- Class Alkynes; Antihyperglycaemics; Piperidines; Purines; Quinazolines; Small molecules
- Mechanism of Action Dipeptidyl peptidase 4 inhibitors; Sodium-glucose transporter 2 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Type 2 diabetes mellitus
Most Recent Events
- 31 Dec 2022 Eli Lilly has patent protection for empagliflozin/linagliptin in USA until 2028
- 08 Sep 2021 Launched for Type 2 diabetes mellitus in Malaysia, Turkey, Israel, United Kingdom, Philippines, Philippines, Canada, Russia, Australia, Greece, Austria, Switzerland, Poland, Spain, Netherlands, Sweden, Denmark, Hong Kong, Norway, Iceland (PO) prior to September 2021
- 08 Sep 2021 Registered for Type 2 diabetes mellitus in Malaysia, Philippines, Canada, Russia, United Kingdom, Israel, Turkey, Australia, Switzerland, Hong Kong (PO) prior to September 2021